Management of Nasal Congestion in Viral Upper Respiratory Infections

Introduction to Treatment Options

The American Academy of Allergy, Asthma, and Immunology recommends against using antihistamine-decongestant combinations for treating nasal congestion in viral upper respiratory infections, as they are ineffective and provide no additive benefit over decongestants alone 1, 2
The European Rhinologic Society found that antihistamines have no additive effect over standard treatment in post-viral acute rhinosinusitis, with very low quality evidence unable to support their use 4, 5

Controlled trials consistently show that antihistamine-decongestant combination products are not effective for symptoms of upper respiratory tract infections 1, 2, 3
Antihistamines have a limited role in treating nonallergic rhinitis syndromes and viral infections because these conditions lack the histamine-mediated inflammatory component present in allergic rhinitis 6

Oral decongestants like pseudoephedrine help reduce nasal congestion in both allergic and nonallergic rhinitis and are beneficial for viral infections 6
The American Academy of Allergy, Asthma, and Immunology recommends oral decongestant alone, such as pseudoephedrine 60mg every 4-6 hours, for symptomatic relief of nasal congestion in adults and children over 12 years 6

Oral decongestants can cause insomnia, loss of appetite, irritability, and palpitations 6
Hypertensive patients should be monitored when using oral decongestants, though blood pressure elevation is rarely noted in normotensive patients and only occasionally in those with controlled hypertension 6

Topical decongestants, such as oxymetazoline, are appropriate for short-term use (maximum 3-5 days) for nasal congestion associated with acute viral infections 1, 2, 7
Rhinitis medicamentosa (rebound congestion) may develop as early as the third day of regular use of topical decongestants, making it essential to limit use to 3-5 days maximum 1, 2, 3

For children under 6 years of age, OTC cough and cold medications, including antihistamine-decongestant combinations, should be avoided entirely due to lack of established efficacy and documented fatalities 1, 2, 3
Between 1969-2006, there were 54 decongestant-related fatalities and 69 antihistamine-related fatalities in children ≤6 years, primarily from overdose errors 1, 2, 3

For adults and children >12 years with viral URI and nasal congestion, first-line treatment is oral pseudoephedrine 60mg every 4-6 hours as needed for congestion relief, with screening for hypertension, glaucoma, and urinary retention contraindications 6
Alternative treatment is topical decongestant (oxymetazoline) for maximum 3 days if rapid relief is needed, with explicit warning about rebound congestion risk 1, 2, 7